Association of 1-deoxy-sphingolipids with ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease
Auteur(s) :
Weyler, J. [Auteur correspondant]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Verrijken, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Hornemann, T. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Universität Zürich [Zürich] = University of Zurich [UZH]
Vonghia, L. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Dirinck, E. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
von Eckardstein, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Universität Zürich [Zürich] = University of Zurich [UZH]
Vanwolleghem, T. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Michielsen, P. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Peiffer, F. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Driessen, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Hubens, G. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Staels, B. [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Francque, S. [Auteur correspondant]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
van Gaal, L. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Verrijken, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Hornemann, T. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Universität Zürich [Zürich] = University of Zurich [UZH]
Vonghia, L. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Dirinck, E. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
von Eckardstein, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Universität Zürich [Zürich] = University of Zurich [UZH]
Vanwolleghem, T. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Michielsen, P. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Peiffer, F. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Driessen, A. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Hubens, G. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Staels, B. [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Francque, S. [Auteur correspondant]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
van Gaal, L. [Auteur]
Antwerp University Hospital [Edegem] [UZA]
University of Antwerp [UA]
Titre de la revue :
Acta Diabetologica
Pagination :
319-327
Éditeur :
Springer Verlag
Date de publication :
2020-10-21
ISSN :
0940-5429
Mot(s)-clé(s) en anglais :
1-Deoxy-sphingolipids
Metabolic syndrome
Non-alcoholic fatty liver disease
Type 2 diabetes mellitus
Metabolic syndrome
Non-alcoholic fatty liver disease
Type 2 diabetes mellitus
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by inflammation and cell damage (non-alcoholic steatohepatitis, ...
Lire la suite >Background: Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by inflammation and cell damage (non-alcoholic steatohepatitis, NASH), and even liver fibrosis. Sphingolipids are a heterogeneous class of lipids and essential components of the plasma membrane and plasma lipoproteins. The atypical class of deoxy-sphingolipids has been implicated in the metabolic syndrome and type 2 diabetes.Aim: To determine if circulating (deoxy)sphingolipids are associated with NAFLD and its different entities, steatosis, inflammatory changes (inflammation and ballooning) and fibrosis.Methods: Sphingolipids were analysed by LC-MS after hydrolysing the N-acyl and O-linked headgroups in plasma of obese adults who underwent a liver biopsy in suspicion of NAFLD.Results: Two-hundred and eighty-eight patients were included. There was no association between typical sphingolipids and NAFLD and its different entities. There was a significant association between the presence of steatosis and the concentrations of deoxy-sphinganine [exp(B) 11.163 with CI (3.432, 36.306) and p < 0.001] and deoxy-sphingosine [exp(B) 8.486 with CI (3.437, 20.949) and p < 0.001]. There was no association between these deoxy-sphingolipids and activity of the steatohepatitis, nor was there any association with fibrosis. Differences in deoxy-sphingolipids also correlated independently with the presence of the metabolic syndrome, but not diabetes.Conclusion: Deoxy-sphingolipids are elevated in patients with steatosis compared to those without fatty liver, but not different between the different NAFLD subtypes, suggesting that deoxy-sphingolipid bases might be involved in steatogenesis, but not in the further progression of NAFLD to NASH nor in fibrogenesis.Lire moins >
Lire la suite >Background: Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by inflammation and cell damage (non-alcoholic steatohepatitis, NASH), and even liver fibrosis. Sphingolipids are a heterogeneous class of lipids and essential components of the plasma membrane and plasma lipoproteins. The atypical class of deoxy-sphingolipids has been implicated in the metabolic syndrome and type 2 diabetes.Aim: To determine if circulating (deoxy)sphingolipids are associated with NAFLD and its different entities, steatosis, inflammatory changes (inflammation and ballooning) and fibrosis.Methods: Sphingolipids were analysed by LC-MS after hydrolysing the N-acyl and O-linked headgroups in plasma of obese adults who underwent a liver biopsy in suspicion of NAFLD.Results: Two-hundred and eighty-eight patients were included. There was no association between typical sphingolipids and NAFLD and its different entities. There was a significant association between the presence of steatosis and the concentrations of deoxy-sphinganine [exp(B) 11.163 with CI (3.432, 36.306) and p < 0.001] and deoxy-sphingosine [exp(B) 8.486 with CI (3.437, 20.949) and p < 0.001]. There was no association between these deoxy-sphingolipids and activity of the steatohepatitis, nor was there any association with fibrosis. Differences in deoxy-sphingolipids also correlated independently with the presence of the metabolic syndrome, but not diabetes.Conclusion: Deoxy-sphingolipids are elevated in patients with steatosis compared to those without fatty liver, but not different between the different NAFLD subtypes, suggesting that deoxy-sphingolipid bases might be involved in steatogenesis, but not in the further progression of NAFLD to NASH nor in fibrogenesis.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Projet Européen :
Hepatic and adipose tissue and functions in the metabolic syndrome
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol
Bile acid, immune-metabolism, lipid and glucose homeostasis
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol
Bile acid, immune-metabolism, lipid and glucose homeostasis
Source :
Fichiers
- https://www.hal.inserm.fr/inserm-03180573/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-03180573/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-03180573/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Weyler%20NAFLD_Acta%20Diabetologica.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Weyler%20NAFLD_Acta%20Diabetologica.pdf
- Accès libre
- Accéder au document